English

ORAMED PHARMACEUTICALS INC.

EDGAR

ORMP Quarterly report (10-Q) · filed 2026-08-10

Annual consolidated revenue for 2026: about USD 2M, using the latest reported figures. The previous period, 2024, was about USD 1.34M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026 Q4 · USD

Exact inputs and evidence

Revenue: 2000000 USD Source
Revenue: 2000000 USD Source

Operating cash flow

-466 thousand USD

2026 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -9145000 USD Source
Operating Cash Flow: -8679000 USD Source

Free cash flow

-468 thousand USD

2026 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -9145000 USD Source
Operating Cash Flow: -8679000 USD Source
Capital Expenditure: 9000 USD Source
Capital Expenditure: 7000 USD Source

Cash and cash equivalents: 15.2 million uref_1598195984 2026-06-30 Source
Exact value

15245000 uref_1598195984
Long-term debt including current maturities: 74.6 million USD 2023-09-30 Source
Exact value

74550000 USD
Shares outstanding: 41.3 million uref_1152718546 2026-06-30 Source
Exact value

41314211 uref_1152718546

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

2 million USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Revenue: 2000000 USD · 2025-01-01 – 2025-03-31 Source
Revenue: 2000000 USD · 2025-01-01 – 2025-06-30 Source
Revenue: 2000000 USD · 2025-01-01 – 2025-03-31 Source
Revenue: 2000000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 2000000 USD · 2025-01-01 – 2025-06-30 Source
Revenue: 2000000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 2000000 USD · 2025-01-01 – 2025-09-30 Source

Operating cash flow

-8.54 million USD

2025-04-01 – 2026-03-31

Exact inputs and evidence

Operating cash flow: -7054000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -3519000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -8679000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -7054000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -9145000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -8679000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -2915000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

11 thousand USD

2025-04-01 – 2026-03-31

Exact inputs and evidence

Capital expenditure: 7000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 3000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 7000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 7000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 9000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 7000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 5000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-8.55 million USD

2025-04-01 – 2026-03-31

Exact inputs and evidence

Operating cash flow: -7054000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -3519000 USD · 2025-01-01 – 2025-03-31 Source
Operating cash flow: -8679000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -7054000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -9145000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -8679000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -2915000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 7000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 3000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 7000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 7000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 9000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 7000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 5000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-10.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 9 of 11 periods available· newest 2025-12-31
Operating income: 10 of 11 periods available· newest 2025-12-31
Net income: 10 of 11 periods available· newest 2025-12-31
Operating cash flow: 10 of 11 periods available· newest 2025-12-31
Capital expenditure: 10 of 11 periods available· newest 2025-12-31
Total assets: Multiple units; comparison withheld· newest 2025-12-31
liabilities: No compatible figures in this window
Current assets: Multiple units; comparison withheld· newest 2025-12-31
Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
Long-term debt including current maturities: 4 of 11 periods available· newest 2022-12-31
Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 83.11 million

Prior period

−USD 19.06 million

2024-01-01 – 2024-12-31
Current period

USD 64.05 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

64050000 − -19060000 = 83110000 USD

-19060000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
64050000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ORAMED PHARMACEUTICALS INC. · 2025-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Year-over-year change in Net income: 83110000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 64050000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#1443065 Filing: 000121390026034835 Input fundies:NetIncome: -19060000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#1443418 Filing: 000121390026034835
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 733,000

Prior period

−USD 8.41 million

2024-01-01 – 2024-12-31
Current period

−USD 9.15 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-9145000 − -8412000 = -733000 USD

-8412000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-9145000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ORAMED PHARMACEUTICALS INC. · 2025-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Year-over-year change in Operating cash flow: -733000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -9145000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#920599 Filing: 000121390026034835 Input fundies:OperatingCashFlow: -8412000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#921054 Filing: 000121390026034835
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-50%

Prior period

USD 18,000

2024-01-01 – 2024-12-31
Current period

USD 9,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

9000 − 18000 = -9000 USD

18000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
9000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ORAMED PHARMACEUTICALS INC. · 2025-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Year-over-year change in Capital expenditure: -9000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 9000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#922004 Filing: 000121390026034835 Input fundies:CapitalExpenditure: 18000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#922325 Filing: 000121390026034835
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2026 2025-01-01 – 2025-12-31

Revenue USD 2 million 100% of revenue
Operating costs Derived USD 17.09 million 854% of revenue
Operating income −USD 15.09 million −754% of revenue
Tax, interest and other Derived −USD 79.14 million −3,957% of revenue
Net income USD 64.05 million 3,203% of revenue

Cash

Operating cash flow −USD 9.15 million −457% of revenue
Capital expenditure USD 9,000 0.5% of revenue
Free cash flow Derived −USD 9.15 million −458% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 1,662% of revenue.
2017 Operating loss: operating costs were 539% of revenue.
2018 Operating loss: operating costs were 652% of revenue.
2019 Operating loss: operating costs were 641% of revenue.
2020 Operating loss: operating costs were 534% of revenue.
2021 Operating loss: operating costs were 996% of revenue.
2023 Operating loss: operating costs were 1,602% of revenue.
2024 Operating loss: operating costs were 1,277% of revenue.
2026 Operating loss: operating costs were 854% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2015-09-01 – 2016-08-31	641000	10651000 Derived	-10010000	954000 Derived	-10964000	4646000 Derived	Source 2015-09-01 – 2016-08-31: 641000 USD Inspect Revenue Open source 2015-09-01 – 2016-08-31: -10010000 USD Inspect Operating Income Open source 2015-09-01 – 2016-08-31: -10964000 USD Inspect Net Income Open source 2015-09-01 – 2016-08-31: 4655000 USD Inspect Operating Cash Flow Open source 2015-09-01 – 2016-08-31: 9000 USD Inspect Capital Expenditure Open source
2017 2016-09-01 – 2017-08-31	2456000	13227000 Derived	-10771000	-291000 Derived	-10480000	-5838000 Derived	Source 2016-09-01 – 2017-08-31: 2456000 USD Inspect Revenue Open source 2016-09-01 – 2017-08-31: -10771000 USD Inspect Operating Income Open source 2016-09-01 – 2017-08-31: -10480000 USD Inspect Net Income Open source 2016-09-01 – 2017-08-31: -5831000 USD Inspect Operating Cash Flow Open source 2016-09-01 – 2017-08-31: 7000 USD Inspect Capital Expenditure Open source
2018 2017-09-01 – 2018-08-31	2449000	15976000 Derived	-13527000	-800000 Derived	-12727000	-14662000 Derived	Source 2017-09-01 – 2018-08-31: 2449000 USD Inspect Revenue Open source 2017-09-01 – 2018-08-31: -13527000 USD Inspect Operating Income Open source 2017-09-01 – 2018-08-31: -12727000 USD Inspect Net Income Open source 2017-09-01 – 2018-08-31: -14657000 USD Inspect Operating Cash Flow Open source 2017-09-01 – 2018-08-31: 5000 USD Inspect Capital Expenditure Open source
2019 2018-09-01 – 2019-08-31	2703000	17334000 Derived	-14631000	-276000 Derived	-14355000	-12955000 Derived	Source 2018-09-01 – 2019-08-31: 2703000 USD Inspect Revenue Open source 2018-09-01 – 2019-08-31: -14631000 USD Inspect Operating Income Open source 2018-09-01 – 2019-08-31: -14355000 USD Inspect Net Income Open source 2018-09-01 – 2019-08-31: -12940000 USD Inspect Operating Cash Flow Open source 2018-09-01 – 2019-08-31: 15000 USD Inspect Capital Expenditure Open source
2020 2019-09-01 – 2020-08-31	2710000	14467000 Derived	-11757000	-246000 Derived	-11511000	-12522000 Derived	Source 2019-09-01 – 2020-08-31: 2710000 USD Inspect Revenue Open source 2019-09-01 – 2020-08-31: -11757000 USD Inspect Operating Income Open source 2019-09-01 – 2020-08-31: -11511000 USD Inspect Net Income Open source 2019-09-01 – 2020-08-31: -12440000 USD Inspect Operating Cash Flow Open source 2019-09-01 – 2020-08-31: 82000 USD Inspect Capital Expenditure Open source
2021 2020-09-01 – 2021-08-31	2703000	26926000 Derived	-24223000	-1234000 Derived	-22989000	-21556000 Derived	Source 2020-09-01 – 2021-08-31: 2703000 USD Inspect Revenue Open source 2020-09-01 – 2021-08-31: -24223000 USD Inspect Operating Income Open source 2020-09-01 – 2021-08-31: -22989000 USD Inspect Net Income Open source 2020-09-01 – 2021-08-31: -21181000 USD Inspect Operating Cash Flow Open source 2020-09-01 – 2021-08-31: 375000 USD Inspect Capital Expenditure Open source
2023 2022-01-01 – 2022-12-31	2703000	43301000 Derived	-40598000	-4037000 Derived	-36561000	-28414000 Derived	Source 2022-01-01 – 2022-12-31: 2703000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -40598000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -36561000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -27918000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 496000 USD Inspect Capital Expenditure Open source
2024 2023-01-01 – 2023-12-31	1340000	17109000 Derived	-15769000	-20857000 Derived	5088000	-10549000 Derived	Source 2023-01-01 – 2023-12-31: 1340000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -15769000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: 5088000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -10295000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 254000 USD Inspect Capital Expenditure Open source
2026 2025-01-01 – 2025-12-31	2000000	17088000 Derived	-15088000	-79138000 Derived	64050000	-9154000 Derived	Source 2025-01-01 – 2025-12-31: 2000000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -15088000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: 64050000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -9145000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 9000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 2M 2026

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-08-31	Revenue	641000	Revenue: 641000 Open source
20172017-08-31	Revenue	2456000	Revenue: 2456000 Open source
20182018-08-31	Revenue	2449000	Revenue: 2449000 Open source
20192019-08-31	Revenue	2703000	Revenue: 2703000 Open source
20202020-08-31	Revenue	2710000	Revenue: 2710000 Open source
20212021-08-31	Revenue	2703000	Revenue: 2703000 Open source
20232022-12-31	Revenue	2703000	Revenue: 2703000 Open source
20242023-12-31	Revenue	1340000	Revenue: 1340000 Open source
20262025-12-31	Revenue	2000000	Revenue: 2000000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-50.4% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-08-31	Year over year	No prior comparable period	Revenue: 641000 Open source
20172017-08-31	Year over year	283.2%	Revenue: 2456000 Open source Revenue: 641000 Open source
20182018-08-31	Year over year	-0.3%	Revenue: 2449000 Open source Revenue: 2456000 Open source
20192019-08-31	Year over year	10.4%	Revenue: 2703000 Open source Revenue: 2449000 Open source
20202020-08-31	Year over year	0.3%	Revenue: 2710000 Open source Revenue: 2703000 Open source
20212021-08-31	Year over year	-0.3%	Revenue: 2703000 Open source Revenue: 2710000 Open source
20232022-12-31	Year over year	No prior comparable period	Revenue: 2703000 Open source
20242023-12-31	Year over year	-50.4%	Revenue: 1340000 Open source Revenue: 2703000 Open source
20262025-12-31	Year over year	No prior comparable period	Revenue: 2000000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -754.4% 2026

Net margin 3,202.5% 2026

Free cash flow margin -457.7% 2026

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-08-31	Operating margin	-1,561.6%	Operating Income: -10010000 Open source Revenue: 641000 Open source
20172017-08-31	Operating margin	-438.6%	Operating Income: -10771000 Open source Revenue: 2456000 Open source
20182018-08-31	Operating margin	-552.3%	Operating Income: -13527000 Open source Revenue: 2449000 Open source
20192019-08-31	Operating margin	-541.3%	Operating Income: -14631000 Open source Revenue: 2703000 Open source
20202020-08-31	Operating margin	-433.8%	Operating Income: -11757000 Open source Revenue: 2710000 Open source
20212021-08-31	Operating margin	-896.2%	Operating Income: -24223000 Open source Revenue: 2703000 Open source
20232022-12-31	Operating margin	-1,502%	Operating Income: -40598000 Open source Revenue: 2703000 Open source
20242023-12-31	Operating margin	-1,176.8%	Operating Income: -15769000 Open source Revenue: 1340000 Open source
20262025-12-31	Operating margin	-754.4%	Operating Income: -15088000 Open source Revenue: 2000000 Open source
20162016-08-31	Net margin	-1,710.5%	Net Income: -10964000 Open source Revenue: 641000 Open source
20172017-08-31	Net margin	-426.7%	Net Income: -10480000 Open source Revenue: 2456000 Open source
20182018-08-31	Net margin	-519.7%	Net Income: -12727000 Open source Revenue: 2449000 Open source
20192019-08-31	Net margin	-531.1%	Net Income: -14355000 Open source Revenue: 2703000 Open source
20202020-08-31	Net margin	-424.8%	Net Income: -11511000 Open source Revenue: 2710000 Open source
20212021-08-31	Net margin	-850.5%	Net Income: -22989000 Open source Revenue: 2703000 Open source
20232022-12-31	Net margin	-1,352.6%	Net Income: -36561000 Open source Revenue: 2703000 Open source
20242023-12-31	Net margin	379.7%	Net Income: 5088000 Open source Revenue: 1340000 Open source
20262025-12-31	Net margin	3,202.5%	Net Income: 64050000 Open source Revenue: 2000000 Open source
20162016-08-31	Free cash flow margin	724.8%	Revenue: 641000 Open source Operating Cash Flow: 4655000 Open source Capital Expenditure: 9000 Open source
20172017-08-31	Free cash flow margin	-237.7%	Revenue: 2456000 Open source Operating Cash Flow: -5831000 Open source Capital Expenditure: 7000 Open source
20182018-08-31	Free cash flow margin	-598.7%	Revenue: 2449000 Open source Operating Cash Flow: -14657000 Open source Capital Expenditure: 5000 Open source
20192019-08-31	Free cash flow margin	-479.3%	Revenue: 2703000 Open source Operating Cash Flow: -12940000 Open source Capital Expenditure: 15000 Open source
20202020-08-31	Free cash flow margin	-462.1%	Revenue: 2710000 Open source Operating Cash Flow: -12440000 Open source Capital Expenditure: 82000 Open source
20212021-08-31	Free cash flow margin	-797.5%	Revenue: 2703000 Open source Operating Cash Flow: -21181000 Open source Capital Expenditure: 375000 Open source
20232022-12-31	Free cash flow margin	-1,051.2%	Revenue: 2703000 Open source Operating Cash Flow: -27918000 Open source Capital Expenditure: 496000 Open source
20242023-12-31	Free cash flow margin	-787.2%	Revenue: 1340000 Open source Operating Cash Flow: -10295000 Open source Capital Expenditure: 254000 Open source
20262025-12-31	Free cash flow margin	-457.7%	Revenue: 2000000 Open source Operating Cash Flow: -9145000 Open source Capital Expenditure: 9000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -9.1M 2026

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-08-31	Operating cash flow	4655000	Operating Cash Flow: 4655000 Open source
20172017-08-31	Operating cash flow	-5831000	Operating Cash Flow: -5831000 Open source
20182018-08-31	Operating cash flow	-14657000	Operating Cash Flow: -14657000 Open source
20192019-08-31	Operating cash flow	-12940000	Operating Cash Flow: -12940000 Open source
20202020-08-31	Operating cash flow	-12440000	Operating Cash Flow: -12440000 Open source
20212021-08-31	Operating cash flow	-21181000	Operating Cash Flow: -21181000 Open source
20232022-12-31	Operating cash flow	-27918000	Operating Cash Flow: -27918000 Open source
20242023-12-31	Operating cash flow	-10295000	Operating Cash Flow: -10295000 Open source
20262025-12-31	Operating cash flow	-9145000	Operating Cash Flow: -9145000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -9.2M 2026

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-08-31	Free cash flow	4646000	Operating Cash Flow: 4655000 Open source Capital Expenditure: 9000 Open source
20172017-08-31	Free cash flow	-5838000	Operating Cash Flow: -5831000 Open source Capital Expenditure: 7000 Open source
20182018-08-31	Free cash flow	-14662000	Operating Cash Flow: -14657000 Open source Capital Expenditure: 5000 Open source
20192019-08-31	Free cash flow	-12955000	Operating Cash Flow: -12940000 Open source Capital Expenditure: 15000 Open source
20202020-08-31	Free cash flow	-12522000	Operating Cash Flow: -12440000 Open source Capital Expenditure: 82000 Open source
20212021-08-31	Free cash flow	-21556000	Operating Cash Flow: -21181000 Open source Capital Expenditure: 375000 Open source
20232022-12-31	Free cash flow	-28414000	Operating Cash Flow: -27918000 Open source Capital Expenditure: 496000 Open source
20242023-12-31	Free cash flow	-10549000	Operating Cash Flow: -10295000 Open source Capital Expenditure: 254000 Open source
20262025-12-31	Free cash flow	-9154000	Operating Cash Flow: -9145000 Open source Capital Expenditure: 9000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-08-31	Liabilities / assets	Not reported	No source recorded
2017-08-31	Liabilities / assets	Not reported	No source recorded
2018-08-31	Liabilities / assets	Not reported	No source recorded
2019-08-31	Liabilities / assets	Not reported	No source recorded
2020-08-31	Liabilities / assets	Not reported	No source recorded
2021-08-31	Liabilities / assets	Not reported	No source recorded
2022-12-31	Liabilities / assets	Not reported	No source recorded
2023-12-31	Liabilities / assets	Not reported	No source recorded
2025-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2016-08-31	Current assets / current liabilities	Not reported	No source recorded
2017-08-31	Current assets / current liabilities	Not reported	No source recorded
2018-08-31	Current assets / current liabilities	Not reported	No source recorded
2019-08-31	Current assets / current liabilities	Not reported	No source recorded
2020-08-31	Current assets / current liabilities	Not reported	No source recorded
2021-08-31	Current assets / current liabilities	Not reported	No source recorded
2022-12-31	Current assets / current liabilities	Not reported	No source recorded
2023-12-31	Current assets / current liabilities	Not reported	No source recorded
2025-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2015-09-01 – 2016-08-31	−USD 10.96 million Exact value Exact value: -10964000 USD 2015-09-01 – 2016-08-31: -10964000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ORAMED PHARMACEUTICALS INC. · 2016-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Net Income: -10964000 USD Concept: fundies:NetIncome Period: 2015-09-01 to 2016-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ANetIncome&period=2016-08-31&surface=latest&period_type=duration&start=2015-09-01&unit=USD&dimensions= Input fundies:NetIncome: -10964000 USD (2015-09-01 to 2016-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390018016666/ormp-20180831.xml#172685 Filing: 000121390018016666 The citation records this snapshot. The page link may show a newer release later.	USD 4.66 million Exact value Exact value: 4655000 USD 2015-09-01 – 2016-08-31: 4655000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ORAMED PHARMACEUTICALS INC. · 2016-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Operating Cash Flow: 4655000 USD Concept: fundies:OperatingCashFlow Period: 2015-09-01 to 2016-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3AOperatingCashFlow&period=2016-08-31&surface=latest&period_type=duration&start=2015-09-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 4655000 USD (2015-09-01 to 2016-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390018016666/ormp-20180831.xml#202960 Filing: 000121390018016666 The citation records this snapshot. The page link may show a newer release later.	USD 9,000 Exact value Exact value: 9000 USD 2015-09-01 – 2016-08-31: 9000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ORAMED PHARMACEUTICALS INC. · 2016-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Capital Expenditure: 9000 USD Concept: fundies:CapitalExpenditure Period: 2015-09-01 to 2016-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ACapitalExpenditure&period=2016-08-31&surface=latest&period_type=duration&start=2015-09-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9000 USD (2015-09-01 to 2016-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390018016666/ormp-20180831.xml#203596 Filing: 000121390018016666 The citation records this snapshot. The page link may show a newer release later.	USD 4.65 million Calculation and evidence 4655000 − 9000 USD Exact free cash flow: 4646000 USD 2015-09-01 – 2016-08-31: 4655000 USD · Inspect Operating Cash Flow · Source 2015-09-01 – 2016-08-31: 9000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ORAMED PHARMACEUTICALS INC. · 2016-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Free cash flow: 4646000 USD Concept: free-cash-flow Period: 2015-09-01 to 2016-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 4655000 USD (2015-09-01 to 2016-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390018016666/ormp-20180831.xml#202960 Filing: 000121390018016666 Input fundies:CapitalExpenditure: 9000 USD (2015-09-01 to 2016-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390018016666/ormp-20180831.xml#203596 Filing: 000121390018016666 The citation records this snapshot. The page link may show a newer release later.
2017 2016-09-01 – 2017-08-31	−USD 10.48 million Exact value Exact value: -10480000 USD 2016-09-01 – 2017-08-31: -10480000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ORAMED PHARMACEUTICALS INC. · 2017-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Net Income: -10480000 USD Concept: fundies:NetIncome Period: 2016-09-01 to 2017-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ANetIncome&period=2017-08-31&surface=latest&period_type=duration&start=2016-09-01&unit=USD&dimensions= Input fundies:NetIncome: -10480000 USD (2016-09-01 to 2017-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/ormp-20190831.xml#494801 Filing: 000121390019024940 The citation records this snapshot. The page link may show a newer release later.	−USD 5.83 million Exact value Exact value: -5831000 USD 2016-09-01 – 2017-08-31: -5831000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ORAMED PHARMACEUTICALS INC. · 2017-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Operating Cash Flow: -5831000 USD Concept: fundies:OperatingCashFlow Period: 2016-09-01 to 2017-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3AOperatingCashFlow&period=2017-08-31&surface=latest&period_type=duration&start=2016-09-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5831000 USD (2016-09-01 to 2017-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/ormp-20190831.xml#501901 Filing: 000121390019024940 The citation records this snapshot. The page link may show a newer release later.	USD 7,000 Exact value Exact value: 7000 USD 2016-09-01 – 2017-08-31: 7000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ORAMED PHARMACEUTICALS INC. · 2017-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Capital Expenditure: 7000 USD Concept: fundies:CapitalExpenditure Period: 2016-09-01 to 2017-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ACapitalExpenditure&period=2017-08-31&surface=latest&period_type=duration&start=2016-09-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7000 USD (2016-09-01 to 2017-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/ormp-20190831.xml#502482 Filing: 000121390019024940 The citation records this snapshot. The page link may show a newer release later.	−USD 5.84 million Calculation and evidence -5831000 − 7000 USD Exact free cash flow: -5838000 USD 2016-09-01 – 2017-08-31: -5831000 USD · Inspect Operating Cash Flow · Source 2016-09-01 – 2017-08-31: 7000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ORAMED PHARMACEUTICALS INC. · 2017-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Free cash flow: -5838000 USD Concept: free-cash-flow Period: 2016-09-01 to 2017-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5831000 USD (2016-09-01 to 2017-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/ormp-20190831.xml#501901 Filing: 000121390019024940 Input fundies:CapitalExpenditure: 7000 USD (2016-09-01 to 2017-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/ormp-20190831.xml#502482 Filing: 000121390019024940 The citation records this snapshot. The page link may show a newer release later.
2018 2017-09-01 – 2018-08-31	−USD 12.73 million Exact value Exact value: -12727000 USD 2017-09-01 – 2018-08-31: -12727000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ORAMED PHARMACEUTICALS INC. · 2018-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Net Income: -12727000 USD Concept: fundies:NetIncome Period: 2017-09-01 to 2018-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ANetIncome&period=2018-08-31&surface=latest&period_type=duration&start=2017-09-01&unit=USD&dimensions= Input fundies:NetIncome: -12727000 USD (2017-09-01 to 2018-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/ormp-20190831.xml#493942 Filing: 000121390019024940 The citation records this snapshot. The page link may show a newer release later.	−USD 14.66 million Exact value Exact value: -14657000 USD 2017-09-01 – 2018-08-31: -14657000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ORAMED PHARMACEUTICALS INC. · 2018-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Operating Cash Flow: -14657000 USD Concept: fundies:OperatingCashFlow Period: 2017-09-01 to 2018-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3AOperatingCashFlow&period=2018-08-31&surface=latest&period_type=duration&start=2017-09-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14657000 USD (2017-09-01 to 2018-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/ormp-20190831.xml#501497 Filing: 000121390019024940 The citation records this snapshot. The page link may show a newer release later.	USD 5,000 Exact value Exact value: 5000 USD 2017-09-01 – 2018-08-31: 5000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ORAMED PHARMACEUTICALS INC. · 2018-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Capital Expenditure: 5000 USD Concept: fundies:CapitalExpenditure Period: 2017-09-01 to 2018-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ACapitalExpenditure&period=2018-08-31&surface=latest&period_type=duration&start=2017-09-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5000 USD (2017-09-01 to 2018-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/ormp-20190831.xml#502087 Filing: 000121390019024940 The citation records this snapshot. The page link may show a newer release later.	−USD 14.66 million Calculation and evidence -14657000 − 5000 USD Exact free cash flow: -14662000 USD 2017-09-01 – 2018-08-31: -14657000 USD · Inspect Operating Cash Flow · Source 2017-09-01 – 2018-08-31: 5000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ORAMED PHARMACEUTICALS INC. · 2018-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Free cash flow: -14662000 USD Concept: free-cash-flow Period: 2017-09-01 to 2018-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14657000 USD (2017-09-01 to 2018-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/ormp-20190831.xml#501497 Filing: 000121390019024940 Input fundies:CapitalExpenditure: 5000 USD (2017-09-01 to 2018-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/ormp-20190831.xml#502087 Filing: 000121390019024940 The citation records this snapshot. The page link may show a newer release later.
2019 2018-09-01 – 2019-08-31	−USD 14.36 million Exact value Exact value: -14355000 USD 2018-09-01 – 2019-08-31: -14355000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ORAMED PHARMACEUTICALS INC. · 2019-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Net Income: -14355000 USD Concept: fundies:NetIncome Period: 2018-09-01 to 2019-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ANetIncome&period=2019-08-31&surface=latest&period_type=duration&start=2018-09-01&unit=USD&dimensions= Input fundies:NetIncome: -14355000 USD (2018-09-01 to 2019-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390020038924/ormp-20200831.xml#87065 Filing: 000121390020038924 The citation records this snapshot. The page link may show a newer release later.	−USD 12.94 million Exact value Exact value: -12940000 USD 2018-09-01 – 2019-08-31: -12940000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ORAMED PHARMACEUTICALS INC. · 2019-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Operating Cash Flow: -12940000 USD Concept: fundies:OperatingCashFlow Period: 2018-09-01 to 2019-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3AOperatingCashFlow&period=2019-08-31&surface=latest&period_type=duration&start=2018-09-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12940000 USD (2018-09-01 to 2019-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390020038924/ormp-20200831.xml#95491 Filing: 000121390020038924 The citation records this snapshot. The page link may show a newer release later.	USD 15,000 Exact value Exact value: 15000 USD 2018-09-01 – 2019-08-31: 15000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ORAMED PHARMACEUTICALS INC. · 2019-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Capital Expenditure: 15000 USD Concept: fundies:CapitalExpenditure Period: 2018-09-01 to 2019-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ACapitalExpenditure&period=2019-08-31&surface=latest&period_type=duration&start=2018-09-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 15000 USD (2018-09-01 to 2019-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390020038924/ormp-20200831.xml#95857 Filing: 000121390020038924 The citation records this snapshot. The page link may show a newer release later.	−USD 12.96 million Calculation and evidence -12940000 − 15000 USD Exact free cash flow: -12955000 USD 2018-09-01 – 2019-08-31: -12940000 USD · Inspect Operating Cash Flow · Source 2018-09-01 – 2019-08-31: 15000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ORAMED PHARMACEUTICALS INC. · 2019-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Free cash flow: -12955000 USD Concept: free-cash-flow Period: 2018-09-01 to 2019-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12940000 USD (2018-09-01 to 2019-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390020038924/ormp-20200831.xml#95491 Filing: 000121390020038924 Input fundies:CapitalExpenditure: 15000 USD (2018-09-01 to 2019-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390020038924/ormp-20200831.xml#95857 Filing: 000121390020038924 The citation records this snapshot. The page link may show a newer release later.
2020 2019-09-01 – 2020-08-31	−USD 11.51 million Exact value Exact value: -11511000 USD 2019-09-01 – 2020-08-31: -11511000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ORAMED PHARMACEUTICALS INC. · 2020-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Net Income: -11511000 USD Concept: fundies:NetIncome Period: 2019-09-01 to 2020-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ANetIncome&period=2020-08-31&surface=latest&period_type=duration&start=2019-09-01&unit=USD&dimensions= Input fundies:NetIncome: -11511000 USD (2019-09-01 to 2020-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390021062009/f10k2021_oramedpharma.htm#677606 Filing: 000121390021062009 The citation records this snapshot. The page link may show a newer release later.	−USD 12.44 million Exact value Exact value: -12440000 USD 2019-09-01 – 2020-08-31: -12440000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ORAMED PHARMACEUTICALS INC. · 2020-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Operating Cash Flow: -12440000 USD Concept: fundies:OperatingCashFlow Period: 2019-09-01 to 2020-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3AOperatingCashFlow&period=2020-08-31&surface=latest&period_type=duration&start=2019-09-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12440000 USD (2019-09-01 to 2020-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390021062009/f10k2021_oramedpharma.htm#740347 Filing: 000121390021062009 The citation records this snapshot. The page link may show a newer release later.	USD 82,000 Exact value Exact value: 82000 USD 2019-09-01 – 2020-08-31: 82000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ORAMED PHARMACEUTICALS INC. · 2020-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Capital Expenditure: 82000 USD Concept: fundies:CapitalExpenditure Period: 2019-09-01 to 2020-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ACapitalExpenditure&period=2020-08-31&surface=latest&period_type=duration&start=2019-09-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 82000 USD (2019-09-01 to 2020-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390021062009/f10k2021_oramedpharma.htm#741651 Filing: 000121390021062009 The citation records this snapshot. The page link may show a newer release later.	−USD 12.52 million Calculation and evidence -12440000 − 82000 USD Exact free cash flow: -12522000 USD 2019-09-01 – 2020-08-31: -12440000 USD · Inspect Operating Cash Flow · Source 2019-09-01 – 2020-08-31: 82000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ORAMED PHARMACEUTICALS INC. · 2020-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Free cash flow: -12522000 USD Concept: free-cash-flow Period: 2019-09-01 to 2020-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12440000 USD (2019-09-01 to 2020-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390021062009/f10k2021_oramedpharma.htm#740347 Filing: 000121390021062009 Input fundies:CapitalExpenditure: 82000 USD (2019-09-01 to 2020-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390021062009/f10k2021_oramedpharma.htm#741651 Filing: 000121390021062009 The citation records this snapshot. The page link may show a newer release later.
2021 2020-09-01 – 2021-08-31	−USD 22.99 million Exact value Exact value: -22989000 USD 2020-09-01 – 2021-08-31: -22989000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ORAMED PHARMACEUTICALS INC. · 2021-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Net Income: -22989000 USD Concept: fundies:NetIncome Period: 2020-09-01 to 2021-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ANetIncome&period=2021-08-31&surface=latest&period_type=duration&start=2020-09-01&unit=USD&dimensions= Input fundies:NetIncome: -22989000 USD (2020-09-01 to 2021-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390021062009/f10k2021_oramedpharma.htm#677195 Filing: 000121390021062009 The citation records this snapshot. The page link may show a newer release later.	−USD 21.18 million Exact value Exact value: -21181000 USD 2020-09-01 – 2021-08-31: -21181000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ORAMED PHARMACEUTICALS INC. · 2021-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Operating Cash Flow: -21181000 USD Concept: fundies:OperatingCashFlow Period: 2020-09-01 to 2021-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3AOperatingCashFlow&period=2021-08-31&surface=latest&period_type=duration&start=2020-09-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21181000 USD (2020-09-01 to 2021-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390023017837/f10k2022_oramedpharma.htm#854484 Filing: 000121390023017837 The citation records this snapshot. The page link may show a newer release later.	USD 375,000 Exact value Exact value: 375000 USD 2020-09-01 – 2021-08-31: 375000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ORAMED PHARMACEUTICALS INC. · 2021-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Capital Expenditure: 375000 USD Concept: fundies:CapitalExpenditure Period: 2020-09-01 to 2021-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ACapitalExpenditure&period=2021-08-31&surface=latest&period_type=duration&start=2020-09-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 375000 USD (2020-09-01 to 2021-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390023017837/f10k2022_oramedpharma.htm#856260 Filing: 000121390023017837 The citation records this snapshot. The page link may show a newer release later.	−USD 21.56 million Calculation and evidence -21181000 − 375000 USD Exact free cash flow: -21556000 USD 2020-09-01 – 2021-08-31: -21181000 USD · Inspect Operating Cash Flow · Source 2020-09-01 – 2021-08-31: 375000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ORAMED PHARMACEUTICALS INC. · 2021-08-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Free cash flow: -21556000 USD Concept: free-cash-flow Period: 2020-09-01 to 2021-08-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21181000 USD (2020-09-01 to 2021-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390023017837/f10k2022_oramedpharma.htm#854484 Filing: 000121390023017837 Input fundies:CapitalExpenditure: 375000 USD (2020-09-01 to 2021-08-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390023017837/f10k2022_oramedpharma.htm#856260 Filing: 000121390023017837 The citation records this snapshot. The page link may show a newer release later.
2023 2022-01-01 – 2022-12-31	−USD 36.56 million Exact value Exact value: -36561000 USD 2022-01-01 – 2022-12-31: -36561000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ORAMED PHARMACEUTICALS INC. · 2022-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Net Income: -36561000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -36561000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390024020485/ea0200896-10k_oramedph.htm#771536 Filing: 000121390024020485 The citation records this snapshot. The page link may show a newer release later.	−USD 27.92 million Exact value Exact value: -27918000 USD 2022-01-01 – 2022-12-31: -27918000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ORAMED PHARMACEUTICALS INC. · 2022-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Operating Cash Flow: -27918000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -27918000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390024020485/ea0200896-10k_oramedph.htm#847873 Filing: 000121390024020485 The citation records this snapshot. The page link may show a newer release later.	USD 496,000 Exact value Exact value: 496000 USD 2022-01-01 – 2022-12-31: 496000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ORAMED PHARMACEUTICALS INC. · 2022-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Capital Expenditure: 496000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 496000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390024020485/ea0200896-10k_oramedph.htm#849207 Filing: 000121390024020485 The citation records this snapshot. The page link may show a newer release later.	−USD 28.41 million Calculation and evidence -27918000 − 496000 USD Exact free cash flow: -28414000 USD 2022-01-01 – 2022-12-31: -27918000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 496000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ORAMED PHARMACEUTICALS INC. · 2022-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Free cash flow: -28414000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -27918000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390024020485/ea0200896-10k_oramedph.htm#847873 Filing: 000121390024020485 Input fundies:CapitalExpenditure: 496000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390024020485/ea0200896-10k_oramedph.htm#849207 Filing: 000121390024020485 The citation records this snapshot. The page link may show a newer release later.
2024 2023-01-01 – 2023-12-31	USD 5.09 million Exact value Exact value: 5088000 USD 2023-01-01 – 2023-12-31: 5088000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ORAMED PHARMACEUTICALS INC. · 2023-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Net Income: 5088000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: 5088000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000101376225003450/ea0234394-10k_oramed.htm#1046716 Filing: 000101376225003450 The citation records this snapshot. The page link may show a newer release later.	−USD 10.3 million Exact value Exact value: -10295000 USD 2023-01-01 – 2023-12-31: -10295000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ORAMED PHARMACEUTICALS INC. · 2023-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Operating Cash Flow: -10295000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -10295000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000101376225003450/ea0234394-10k_oramed.htm#1062006 Filing: 000101376225003450 The citation records this snapshot. The page link may show a newer release later.	USD 254,000 Exact value Exact value: 254000 USD 2023-01-01 – 2023-12-31: 254000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ORAMED PHARMACEUTICALS INC. · 2023-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Capital Expenditure: 254000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 254000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000101376225003450/ea0234394-10k_oramed.htm#1063538 Filing: 000101376225003450 The citation records this snapshot. The page link may show a newer release later.	−USD 10.55 million Calculation and evidence -10295000 − 254000 USD Exact free cash flow: -10549000 USD 2023-01-01 – 2023-12-31: -10295000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 254000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ORAMED PHARMACEUTICALS INC. · 2023-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Free cash flow: -10549000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -10295000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000101376225003450/ea0234394-10k_oramed.htm#1062006 Filing: 000101376225003450 Input fundies:CapitalExpenditure: 254000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000101376225003450/ea0234394-10k_oramed.htm#1063538 Filing: 000101376225003450 The citation records this snapshot. The page link may show a newer release later.
2025 2024-01-01 – 2024-12-31	−USD 19.06 million Exact value Exact value: -19060000 USD 2024-01-01 – 2024-12-31: -19060000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ORAMED PHARMACEUTICALS INC. · 2024-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Net Income: -19060000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19060000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#1443418 Filing: 000121390026034835 The citation records this snapshot. The page link may show a newer release later.	−USD 8.41 million Exact value Exact value: -8412000 USD 2024-01-01 – 2024-12-31: -8412000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ORAMED PHARMACEUTICALS INC. · 2024-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Operating Cash Flow: -8412000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8412000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#921054 Filing: 000121390026034835 The citation records this snapshot. The page link may show a newer release later.	USD 18,000 Exact value Exact value: 18000 USD 2024-01-01 – 2024-12-31: 18000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ORAMED PHARMACEUTICALS INC. · 2024-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Capital Expenditure: 18000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 18000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#922325 Filing: 000121390026034835 The citation records this snapshot. The page link may show a newer release later.	−USD 8.43 million Calculation and evidence -8412000 − 18000 USD Exact free cash flow: -8430000 USD 2024-01-01 – 2024-12-31: -8412000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 18000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ORAMED PHARMACEUTICALS INC. · 2024-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Free cash flow: -8430000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8412000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#921054 Filing: 000121390026034835 Input fundies:CapitalExpenditure: 18000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#922325 Filing: 000121390026034835 The citation records this snapshot. The page link may show a newer release later.
2026 2025-01-01 – 2025-12-31	USD 64.05 million Exact value Exact value: 64050000 USD 2025-01-01 – 2025-12-31: 64050000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ORAMED PHARMACEUTICALS INC. · 2025-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Net Income: 64050000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: 64050000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#1443065 Filing: 000121390026034835 The citation records this snapshot. The page link may show a newer release later.	−USD 9.15 million Exact value Exact value: -9145000 USD 2025-01-01 – 2025-12-31: -9145000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ORAMED PHARMACEUTICALS INC. · 2025-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Operating Cash Flow: -9145000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9145000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#920599 Filing: 000121390026034835 The citation records this snapshot. The page link may show a newer release later.	USD 9,000 Exact value Exact value: 9000 USD 2025-01-01 – 2025-12-31: 9000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ORAMED PHARMACEUTICALS INC. · 2025-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Capital Expenditure: 9000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#922004 Filing: 000121390026034835 The citation records this snapshot. The page link may show a newer release later.	−USD 9.15 million Calculation and evidence -9145000 − 9000 USD Exact free cash flow: -9154000 USD 2025-01-01 – 2025-12-31: -9145000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 9000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ORAMED PHARMACEUTICALS INC. · 2025-12-31 ORAMED PHARMACEUTICALS INC. (edgar:1176309) Free cash flow: -9154000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T19:30:20Z Snapshot: a5316f86360c0b47b6b9735e364ac2faffeace42269fe55b639a93150e928137 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1176309?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9145000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#920599 Filing: 000121390026034835 Input fundies:CapitalExpenditure: 9000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1176309/000121390026034835/ea0282618-10k_oramed.htm#922004 Filing: 000121390026034835 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

142 filings · 3,413 latest values · 3,413 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001176309, 1176309, ORMP, edgar:1176309

Also known as IGUANA VENTURES LTD, Integrated Security Technologies, Inc., ORAMED PHARMACEUTICALS INC., ORAMED PHARMACEUTICALS INC.

ORAMED PHARMACEUTICALS INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2026 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation